Vaccentis and TrueMed Join Forces for the Advancement of a Cancer Vaccine

Acceleration of the Development of the Cancer Vaccine Against Renal Cell Carcinoma

The aim of this letter of intent is to establish a strategic partnership that will propel the strategic and operational development of Vaccentis. At the heart of this collaboration is the leading vaccine candidate VCC-001 and its platform technology. VCC-001 is a promising, individualized therapeutic vaccine for the adjuvant treatment of renal cell carcinoma. The letter of intent stipulates that TrueMed will support Vaccentis with its existing infrastructure as well as its ongoing search for potential strategic partnerships. During the term of the agreement, Vaccentis grants exclusive rights for the commercialization, sale, and distribution of VCC-001 and future pipeline candidates in Israel.

The combination of Vaccentis' research and development expertise with TrueMed’s comprehensive competencies in business development, investor relations, and strategic alliances is expected to significantly advance the next milestones for VCC-001.

Partnership with Diverse Joint Opportunities

TrueMed and Vaccentis highly value their partnership and are confident in the mutual opportunities that this collaboration will offer.

"VCC-001 is a promising immunotherapeutic approach with tremendous potential to fundamentally improve cancer treatment. With our extensive experience in market introduction and commercialization, as well as our vast investor network, we aim to support Vaccentis in research and development and hopefully bring the vaccine to patients as quickly as possible," say Arie Koren and Shmulik Berkovich, Co-CEOs and founders of TrueMed.

Vaccentis also emphasizes the importance of the impending collaboration: "TrueMed’s support for our mission provides valuable opportunities to further accelerate the development of our product candidate VCC-001 and our tumor vaccine platform technology. Having a sparring partner like TrueMed, with years of expertise and a vast network in the healthcare financial sector, can significantly help us ensure that the first patients can benefit from VCC-001 soon," explain Vaccentis CEO Martin Munte and Vaccentis board member Patrik Grandits.

About TrueMed

TrueMed is a leading commercialization partner for rare diseases and specialty therapies in Israel. The company offers global innovators customized "port-to-patient" solutions from a single source, including early access, smooth market entry, as well as support for patients and caregiving partners.

TrueMed has successfully collaborated with leading companies from the USA and the EU, locally introduced some of the most innovative technologies, enabled broad access, and delivered complex therapies to patients with high needs. For more information, please visit www.TrueMedtx.com.

Press Contact:
Brandenstein Communications
Phone: +43 1 319 41 01-11
Email: presse@brandensteincom.at

Editor's note: Image rights belong to the respective publisher.